August 22nd 2025
Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.
Mastering misoprostol: Comprehensive uses across trimesters
May 17th 2024Leanne R. McCloskey, MD, and Weronika A. Armstrong, MD, xplore the multifaceted applications of misoprostol in obstetrics, covering protocols, safety, and the impact on birth equity from early pregnancy loss to labor induction at ACOG 2024.
Watch
Mail-order dispensing of mifepristone for medication abortion found effective
May 13th 2024A recent study revealed that mail-order pharmacy dispensing of mifepristone for medication abortion proves effective and satisfactory, highlighting a potential avenue for expanding access to reproductive healthcare.
Read More
Contemporary understanding of breast cancer risk with combined oral contraceptives
April 2nd 2024Unveiling the intricate relationship between combined oral contraceptive use and breast cancer risk, navigating through research insights and clinical implications for informed patient counseling.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
Impact of serum estradiol decline before hCG-triggering on IVF outcomes
March 13th 2024A recent study delves into how serum estradiol decline preceding human chorionic gonadotropin administration affects in vitro fertilization outcomes, particularly among patients without oral contraceptive pretreatment, shedding light on the importance of monitoring during controlled ovarian hyperstimulation.
Read More
New guidelines revealed for no-cost FDA-approved contraceptives
January 23rd 2024The Biden-Harris administration, has released comprehensive guidance through Frequently Asked Questions to eliminate barriers to contraception, ensuring access to FDA-approved contraceptives at no cost, following President Biden's 2023 Executive Order.
Read More